scispace - formally typeset
P

Peter Sleight

Researcher at John Radcliffe Hospital

Publications -  260
Citations -  24957

Peter Sleight is an academic researcher from John Radcliffe Hospital. The author has contributed to research in topics: Blood pressure & Myocardial infarction. The author has an hindex of 73, co-authored 260 publications receiving 23935 citations. Previous affiliations of Peter Sleight include University of Oxford & University of Sydney.

Papers
More filters
Journal Article

Collaborative overview of randomized trials of antiplatelet therapy .1. prevention of death, myocardial-infarction, and stroke by prolonged antiplatelet therapy in various categories of patients

R Altman, +418 more
- 08 Jan 1994 - 
TL;DR: There was no appreciable evidence that either a higher aspirin dose or any other antiplatelet regimen was more effective than medium dose aspirin in preventing vascular events, so in each of the four main high risk categories overall mortality was significantly reduced.
Journal ArticleDOI

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial

TL;DR: Reduction of LDL cholesterol with simvastatin 20 mg plus ezetimibe 10 mg daily safely reduced the incidence of major atherosclerotic events in a wide range of patients with advanced chronic kidney disease.
Journal ArticleDOI

Changes in autonomic regulation induced by physical training in mild hypertension.

TL;DR: The index a is proposed as a quantitative indicator of the changes in the gain of baroreceptor mechanisms occurring with physical training in mild hypertension and during a 24-hour period in ambulatory subjects.
Journal ArticleDOI

Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial.

TL;DR: The CONVINCE trial did not demonstrate equivalence of a COER verapamil–based antihypertensive regimen compared with a regimen beginning with a diuretic or -blocker, and data indicate that the effectiveness of calcium-channel therapy in reducing cardiovascular disease is similar but not better than diuresis treatment.